Medexus Pharmaceuticals Inc. (TSE:MDP – Free Report) – Investment analysts at Raymond James dropped their Q3 2026 EPS estimates for shares of Medexus Pharmaceuticals in a report released on Tuesday, January 7th. Raymond James analyst M. Freeman now forecasts that the company will post earnings per share of $0.22 for the quarter, down from their previous estimate of $0.24. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.
A number of other research analysts have also commented on the company. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and a consensus target price of C$5.25.
Medexus Pharmaceuticals Price Performance
Shares of Medexus Pharmaceuticals stock opened at C$4.04 on Thursday. The firm has a 50 day simple moving average of C$2.77 and a 200 day simple moving average of C$2.53. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$4.24. The firm has a market cap of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
- Five stocks we like better than Medexus Pharmaceuticals
- Energy and Oil Stocks Explained
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Are the U.K. Market Holidays? How to Invest and Trade
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.